{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:15:44Z","timestamp":1777716944875,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.biopha.2013.11.003","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T21:30:26Z","timestamp":1385933426000},"page":"191-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells"],"prefix":"10.1016","volume":"68","author":[{"given":"Peeyush N.","family":"Goel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv P.","family":"Gude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2013.11.003_bib0005","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.biopha.2013.11.003_bib0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2013.11.003_bib0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0020","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.yexcr.2013.02.012","article-title":"New insights into organ-specific extravasation and metastatic niches","volume":"319","author":"Irmisch","year":"2013","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.biopha.2013.11.003_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","article-title":"Triple negative breast cancer: disease entity or title of convenience?","volume":"7","author":"Carey","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12609-012-0097-1","article-title":"Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: an overview","volume":"5","author":"Andreopoulou","year":"2013","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.biopha.2013.11.003_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"10.1016\/j.biopha.2013.11.003_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd3473","article-title":"Could pharma open its drug freezers?","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopha.2013.11.003_bib0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bcp.2004.05.026","article-title":"Phosphodiesterase inhibitors as anti-cancer drugs","volume":"68","author":"Hirsh","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0050","first-page":"103","article-title":"Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases","volume":"9","author":"Zhang","year":"2004","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0055","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12032-007-0006-z","article-title":"Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer","volume":"24","author":"Misirlioglu","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0060","first-page":"13","article-title":"Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65","volume":"20","author":"Bravo-Cuellar","year":"2013","journal-title":"J Bio Sci"},{"key":"10.1016\/j.biopha.2013.11.003_bib0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-005-0155-8","article-title":"Anti-proliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells","volume":"58","author":"Dua","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11010-011-0929-8","article-title":"Unravelling the anti-metastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells","volume":"358","author":"Goel","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.biopha.2013.11.003_bib0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejphar.2013.07.004","article-title":"Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells","volume":"714","author":"Goel","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0080","article-title":"Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells","author":"Goel","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2013.11.003_bib0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.biopha.2013.11.003_bib0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1476-4598-9-114","article-title":"Sensitization of cervix cancer cells to adriamycin by pentoxifylline induces an increase in apoptosis and decrease senescence","volume":"9","author":"Bravo-Cuellar","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.biopha.2013.11.003_bib0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.imlet.2005.10.019","article-title":"In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation","volume":"103","author":"Lerma-Diaz","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1016\/j.biopha.2013.11.003_bib0110","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s11095-013-1093-5","article-title":"Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond","volume":"30","author":"Manjappa","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.biopha.2013.11.003_bib0115","series-title":"CompuSyn Software for drug combinations and for general dose-effect analysis and user's guide","author":"Chou","year":"2007"},{"key":"10.1016\/j.biopha.2013.11.003_bib0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6750-5-12","article-title":"A simple technique for quantifying apoptosis in 96-well plates","volume":"5","author":"Ribble","year":"2005","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0125","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","article-title":"Highly efficacious nontoxic pre-clinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy","volume":"66","author":"Munoz","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2013.11.003_bib0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopha.2003.09.003","article-title":"Advanced breast cancer: an update and controversies on diagnosis and therapy","volume":"57","author":"Nicolini","year":"2003","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2013.11.003_bib0135","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.biopha.2006.07.086","article-title":"Metastatic breast cancer: an updating","volume":"60","author":"Nicolini","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2013.11.003_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1359-6349(11)70004-0","article-title":"Anthracyclines in the management of metastatic breast cancer: state of the art","volume":"9","author":"Gennari","year":"2011","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.biopha.2013.11.003_bib0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jps.2600840411","article-title":"Programmable drug release of highly water-soluble pentoxifylline from dry-coated wax matrix tablets","volume":"84","author":"Otsuka","year":"1995","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopha.2013.11.003_bib0150","first-page":"669","article-title":"Different expression of extracellular signal-regulated kinases (ERK) 1\/2 and phospho-Erk proteins in MBA-MB-231 and MCF-7 cells after chemotherapy with doxorubicin or docetaxel","volume":"15","author":"Taherian","year":"2012","journal-title":"Iran J of Basic Med Sci"},{"key":"10.1016\/j.biopha.2013.11.003_bib0155","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/CAD.0b013e3282ef4571","article-title":"Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells","volume":"18","author":"Bar-On","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2013.11.003_bib0160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrc2622","article-title":"Metastasis: from dissemination to organ-specific colonization","volume":"9","author":"Nguyen","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biopha.2013.11.003_bib0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.pathmechdis.3.121806.151523","article-title":"Metastatic cancer cell","volume":"3","author":"Bacac","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0170","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1083\/jcb.111.4.1685","article-title":"Molecular heterogeneity of basal laminae: isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere","volume":"111","author":"Sanes","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.biopha.2013.11.003_bib0175","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1054\/bjoc.2001.1810","article-title":"Overexpression of matrix metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients","volume":"84","author":"Scorilas","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2013.11.003_bib0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2144\/05381RV01","article-title":"Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors","volume":"38","author":"Snoek-van Beurden","year":"2005","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2013.11.003_bib0185","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-06-0391","article-title":"Tumor models for efficacy determination","volume":"5","author":"Teicher","year":"2006","journal-title":"Mol Cancer Ther"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332213001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332213001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:52:13Z","timestamp":1760093533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332213001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0753332213001327"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2013.11.003","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2013.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}